L 410198

Drug Profile

L 410198

Latest Information Update: 05 Oct 2006

Price : $50

At a glance

  • Originator Merck & Co
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hyperlipidaemia; Type 2 diabetes mellitus

Most Recent Events

  • 31 Dec 2004 Discontinued - Clinical-Phase-Unknown for Hyperlipidaemia in USA (unspecified route)
  • 31 Dec 2004 Discontinued - Clinical-Phase-Unknown for Type-2 diabetes mellitus in USA (unspecified route)
  • 26 Feb 2002 Clinical trials in Hyperlipidaemia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top